Metformin versus SGLT-2 inhibitors: how low can we go?

Menno Pruijm; Olivier Phan; Anne Zanchi

doi:10.1016/j.kint.2022.02.012

Metformin versus SGLT-2 inhibitors: how low can we go?

Kidney Int. 2022 May;101(5):874-877. doi: 10.1016/j.kint.2022.02.012.

Authors

Menno Pruijm¹, Olivier Phan², Anne Zanchi³

Affiliations

¹ Service of Nephrology and Hypertension, Lausanne University Hospital and University of Lausanne, Department of Medicine, Lausanne, Switzerland. Electronic address: menno.pruijm@chuv.ch.
² Service of Nephrology and Hypertension, Lausanne University Hospital and University of Lausanne, Department of Medicine, Lausanne, Switzerland.
³ Service of Nephrology and Hypertension, Lausanne University Hospital and University of Lausanne, Department of Medicine, Lausanne, Switzerland; Service of Endocrinology, Diabetes and Metabolism, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.

PMID: 35461613
DOI: 10.1016/j.kint.2022.02.012

Abstract

The progression of chronic kidney disease is difficult to stop once established. Metformin and sodium-glucose cotransporter 2 inhibitors show promise, but clinical trials with a head-to-head comparison in patients with more advanced (stage 3b-4) chronic kidney disease are largely lacking, partly for safety reasons. In this issue, Corremans et al. compare the effects of metformin and canagliflozin in rats with adenine-induced moderate (stage 2-4) chronic kidney disease. Metformin halted progression, whereas canagliflozin did not. This commentary puts the results in a wider clinical context.

Publication types

Comment

MeSH terms

Animals
Canagliflozin / adverse effects
Female
Humans
Hypoglycemic Agents / adverse effects
Male
Metformin* / pharmacology
Metformin* / therapeutic use
Rats
Renal Insufficiency, Chronic* / chemically induced
Renal Insufficiency, Chronic* / drug therapy
Sodium-Glucose Transporter 2 Inhibitors* / therapeutic use

Substances

Canagliflozin
Hypoglycemic Agents
Metformin
Sodium-Glucose Transporter 2 Inhibitors